The drugmaker aims to have 200 employees by the end of this year and 350 the following year. The decision was vital to its plan to maximise its investment in biotech machines. Staff numbers will reportedly stay fixed for up to four years after the increase but will be increased again following the company’s expansion in China.

Glaxo reported last year that it believes that China will become the new crucible of the global biotechnology industry. 

Last update : Wednesday, 09 July 2008

Keywords : Glaxo, R&D, Biotechnology, Innovation

Average user rating

   (0 vote)